BCL9
BCL9 (B-cell CLL/lymphoma 9 protein) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Colorectal cancer, Gastric & gastro-oesophageal junction cancer, Skin cancer and 2 more.
Overview
Involved in signal transduction through the Wnt pathway. Promotes beta-catenin's transcriptional activity.
Open Targets scores its association with cancer at 0.66 (direct and indirect evidence; datatypes literature 0.98, genetic association 0.00, somatic mutation 0.85). IntOGen calls it a driver in 4 cohorts (1 activating, 3 loss-of-function), covering Colon Adenocarcinoma, Colorectal Adenocarcinoma, Stomach Adenocarcinoma.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · BCL9 (B-cell CLL/lymphoma 9 protein) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Colorectal cancer, Gastric & gastro-oesophageal junction cancer, Skin cancer and 2 more.
- 1 · What it is
BCL9 (B-cell CLL/lymphoma 9 protein) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Colorectal cancer, Gastric & gastro-oesophageal junction cancer, Skin cancer and 2 more.
- 2 · What goes wrong in cancer
Involved in signal transduction through the Wnt pathway. Promotes beta-catenin's transcriptional activity.
- 3 · How drugs use it
No product in this corpus aims at BCL9 yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
External identifiers
Sources: HGNC HGNC:1008 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt O00512 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000116128 (association with cancer (MONDO_0004992) 0.66; per-cancer scores at or above 0.5: colorectal cancer 0.57, gastric cancer 0.52, melanoma 0.51, skin cancer 0.54, breast cancer 0.53 (GraphQL API, CC0)); IntOGen BCL9 (driver in 4 cohorts (Act 1, LoF 3); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Involved in signal transduction through the Wnt pathway. Promotes beta-catenin's transcriptional activity. Location: Nucleus (UniProt). Locus 1q21.2 (HGNC).
- Colorectal cancer: Open Targets association 0.57 with colorectal cancer (MONDO_0005575); IntOGen driver in 3 cohorts (COAD, COADREAD)
- Gastric & gastro-oesophageal junction cancer: Open Targets association 0.52 with gastric cancer (MONDO_0001056); IntOGen driver in 1 cohort (STAD)
- Skin cancer: Open Targets association 0.54 with skin cancer (MONDO_0002898)
- Breast cancer: Open Targets association 0.53 with breast cancer (MONDO_0007254)
- Melanoma: Open Targets association 0.51 with melanoma (MONDO_0005105)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 1 cohort; IntOGen calls it a loss-of-function (LoF) driver in 3 cohorts; UniProt disease notes describe a translocation or gene fusion involving the gene. Evidence tier "cohort-driver" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"BCL9" OR ABSTRACT:"BCL9" OR TITLE:"BCL9 transcription coactivator" OR ABSTRACT:"BCL9 transcription coactivator" OR TITLE:"B-cell CLL/lymphoma 9 protein" OR ABSTRACT:"B-cell CLL/lymphoma 9 protein") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about BCL9, not a curated reading list.